Sector
PharmaceuticalsOpen
₹691.05Prev. Close
₹689.35Turnover(Lac.)
₹79.57Day's High
₹698.2Day's Low
₹668.3552 Week's High
₹052 Week's Low
₹0Book Value
₹342.53Face Value
₹5Mkt Cap (₹ Cr.)
1,659.84P/E
24.54EPS
40.87Divi. Yield
2.49Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 12.34 | 12.34 | 12.34 | 12.34 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 732.48 | 763.32 | 679.36 | 698.85 |
Net Worth | 744.82 | 775.66 | 691.7 | 711.19 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 399.87 | 381.35 | 438.25 | 563.88 |
yoy growth (%) | 4.85 | -12.98 | -22.27 | -14.07 |
Raw materials | -178.13 | -146.62 | -182.32 | -245.51 |
As % of sales | 44.54 | 38.44 | 41.6 | 43.53 |
Employee costs | -101.89 | -108.51 | -113.87 | -144.53 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 45.82 | 40.04 | 28.64 | 157.52 |
Depreciation | -9.65 | -12.16 | -13.14 | -2.53 |
Tax paid | 0.1 | -19.14 | -18.56 | -79.16 |
Working capital | -78.83 | -15.29 | -30.38 | -167.55 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.85 | -12.98 | -22.27 | -14.07 |
Op profit growth | 1.19 | 122.69 | -292.48 | -124.96 |
EBIT growth | 6.13 | 36.22 | -78.51 | 76.36 |
Net profit growth | -117.79 | 107.34 | -87.13 | 36.94 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
C Snook
Independent Director
Sandra Martryes
Independent Director
SANKER PARAMESWARAN
Whole Time Director & CFO
Shilpa Joshi
Company Sec. & Compli. Officer
Chandni Maru
Independent Director
Gira Sardesai
Whole Time Director
Falin Majmudar
The Inspire BKC Part 601 & 701,
Bandra Kurla Complex Bandra(E),
Maharashtra - 400051
Tel: 91-022-50243000
Website: http://www.novartis.in
Email: [email protected]
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: [email protected]
Summary
Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the worlds second largest pharmaceutical company was incorporated on 13 December 1947. The Company is engaged in manufacturing and...
Read More
Reports by Novartis India Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.